Amgen publishes positive data from Kyprolis multiple myeloma study

Amgen has announced the publication of new clinical trial data demonstrating the benefits of its cancer drug Kyprolis in the treatment of multiple myeloma.

Published in the Journal of Clinical Oncology, the final analysis from the phase III ASPIRE trial showed that the addition of Kyprolis to lenalidomide and dexamethasone reduced the risk of death by 21 percent versus lenalidomide and dexamethasone alone.

Amgen's drug was also shown to extend overall survival by 7.9 months in patients with relapsed or refractory multiple myeloma, with an overall survival improvement of 11.4 months observed for patients at first relapse.

This treatment regimen is currently approved in the US, EU and other countries based on primary analysis of progression-free survival data from the ASPIRE study. Amgen will now be applying for these approvals to be updated to include the latest ASPIRE findings in the product information for Kyprolis.

Dr David Reese, senior vice-president of translational sciences and oncology at Amgen, said: "Kyprolis-based regimens are the first and only therapy combinations to demonstrate a significant overall survival advantage for patients with relapsed or refractory multiple myeloma versus recent standards of care."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.